OTCPK:HHBT

Stock Analysis Report

HH Biotechnology Holdings

Executive Summary

HH Biotechnology Holdings Company engages in health and green industries.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has HH Biotechnology Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HHBT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

HHBT

-1.4%

US Real Estate

2.4%

US Market


1 Year Return

n/a

HHBT

-36.3%

US Real Estate

-10.0%

US Market

Return vs Industry: Insufficient data to determine how HHBT performed against the US Real Estate industry.

Return vs Market: Insufficient data to determine how HHBT performed against the US Market.


Shareholder returns

HHBTIndustryMarket
7 Day0%-1.4%2.4%
30 Day566.7%-33.5%-11.0%
90 Dayn/a-41.4%-19.4%
1 Yearn/a-35.8%-36.3%-8.1%-10.0%
3 Year-70.0%-70.0%-23.0%-24.9%17.3%9.6%
5 Year-81.0%-81.0%-35.7%-37.6%36.1%21.1%

Price Volatility Vs. Market

How volatile is HH Biotechnology Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is HH Biotechnology Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether HH Biotechnology Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as HH Biotechnology Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HHBT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through HH Biotechnology Holdings regulatory filings here.
  • Explore potentially undervalued companies in the Real Estate industry.

Future Growth

How is HH Biotechnology Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.5%

Forecasted Real Estate industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HH Biotechnology Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HHBT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access HH Biotechnology Holdings's filings and announcements here.
  • Explore growth companies in the Real Estate industry.

Past Performance

How has HH Biotechnology Holdings performed over the past 5 years?

8.4%

Historical Real Estate annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if HHBT has high quality earnings.

Growing Profit Margin: Insufficient data to determine if HHBT's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if HHBT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare HHBT's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if HHBT's earnings growth over the past year exceeded the Real Estate industry average.


Return on Equity

High ROE: HHBT has a negative Return on Equity (0%), as it is currently unprofitable.


Next Steps

Financial Health

How is HH Biotechnology Holdings's financial position?


In this section we usually analyse HH Biotechnology Holdings's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. HH Biotechnology Holdings has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of HHBT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when HH Biotechnology Holdings's financial data was last updated here.
  • Explore more healthy companies in the Real Estate industry.

Dividend

What is HH Biotechnology Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HHBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HHBT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HHBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HHBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HHBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Sheng Jiang

3.58s

Tenure

Mr. Sheng Jiang has been Chief Executive Officer and Director at HH Biotechnology Holdings Company since September 9, 2016. 


Leadership Team

NamePositionTenureCompensationOwnership
Sheng Jiang
Chief Executive Officer and Director3.58yrsno datano data
Li Rong Wang
Chief Financial Officer3.58yrsUS$12.39kno data
Liang Zou
Vice President of Operations3.58yrsno datano data
Yee Tang
Investor Relations Officerno datano datano data
Sasaki Koji
Vice President of Marketing3.58yrsno datano data
Shuang Li
Acting Secretary of The Board3.58yrsno datano data

3.6yrs

Average Tenure

Experienced Management: HHBT's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sheng Jiang
Chief Executive Officer and Director3.58yrsno datano data
Jiang Fang
Chairmanno datano datano data
Yizhao Zhang
Independent Director3.92yrsno datano data
Ying Huang
Director3.58yrsno datano data

3.6yrs

Average Tenure

Experienced Board: HHBT's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

HH Biotechnology Holdings Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HH Biotechnology Holdings Company
  • Ticker: HHBT
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Real Estate Operating Companies
  • Sector: Real Estate
  • Market Cap: US$8.436m
  • Shares outstanding: 14.06m
  • Website: https://www.greatchinaholdings.com

Number of Employees


Location

  • HH Biotechnology Holdings Company
  • President Building
  • C Site, 25-26 Floors
  • Shenyang
  • Liaoning Province
  • 110003
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HHBTOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2005

Biography

HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the People’s Republic of China. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 04:35
End of Day Share Price2020/03/20 00:00
Earnings2016/09/30
Annual Earnings2015/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.